Patent · US Active

Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

US12365729B2 · kind B2 · utility

0Cited by

305References

30Claims

0Family size

Assignees

Disc Medicine, Inc. · US
Abb Vie Inc. · US
Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

Maria Beconi · Bedford, US
John Quisel · Cambridge, US
Brian MacDonald · Cambridge, US
Steven Robinette · Fremont, US
Bernhard Mueller · Neustadt, DE
Andreas Popp · Ludwigshafen, DE
Jennifer M. Perez · Worcester, US

Key dates

Filing date	Sep 25, 2024
Grant date	Jul 22, 2025
Priority date	—
Expiry date	Sep 25, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.